X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (58844) 58844
Book Review (13444) 13444
Publication (2296) 2296
Newspaper Article (1316) 1316
Newsletter (1114) 1114
Magazine Article (489) 489
Book Chapter (217) 217
Conference Proceeding (199) 199
Trade Publication Article (163) 163
Book / eBook (81) 81
Web Resource (53) 53
Transcript (45) 45
Dissertation (13) 13
Paper (6) 6
Data Set (5) 5
Reference (3) 3
Government Document (1) 1
Presentation (1) 1
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50649) 50649
index medicus (48878) 48878
anticoagulants - therapeutic use (37408) 37408
female (23145) 23145
male (22461) 22461
anticoagulants (20805) 20805
middle aged (15920) 15920
aged (15258) 15258
adult (11607) 11607
risk factors (9669) 9669
anticoagulants - adverse effects (9494) 9494
abridged index medicus (8530) 8530
warfarin (8440) 8440
treatment outcome (8388) 8388
anticoagulants - administration & dosage (7842) 7842
hematology (7062) 7062
peripheral vascular disease (6874) 6874
cardiac & cardiovascular systems (6863) 6863
thrombosis (6661) 6661
warfarin - therapeutic use (6579) 6579
heparin - therapeutic use (6296) 6296
aged, 80 and over (5907) 5907
stroke (5898) 5898
thromboembolism (5682) 5682
atrial fibrillation (5547) 5547
medicine, general & internal (5190) 5190
surgery (5190) 5190
prevention (5114) 5114
retrospective studies (4788) 4788
anticoagulation (4619) 4619
heparin (4556) 4556
animals (4443) 4443
risk (4391) 4391
therapy (4343) 4343
atrial fibrillation - drug therapy (4342) 4342
pharmacology & pharmacy (4314) 4314
care and treatment (4256) 4256
venous thromboembolism (4166) 4166
platelet aggregation inhibitors - therapeutic use (4103) 4103
time factors (4012) 4012
administration, oral (3986) 3986
drug therapy (3954) 3954
management (3901) 3901
hemorrhage - chemically induced (3747) 3747
fibrinolytic agents - therapeutic use (3654) 3654
analysis (3558) 3558
stroke - prevention & control (3530) 3530
thromboembolism - prevention & control (3496) 3496
atrial fibrillation - complications (3404) 3404
mortality (3364) 3364
medicine & public health (3319) 3319
molecular-weight heparin (3252) 3252
prospective studies (3244) 3244
heparin, low-molecular-weight - therapeutic use (3214) 3214
health aspects (3152) 3152
follow-up studies (3134) 3134
anticoagulants - pharmacology (3083) 3083
patients (3078) 3078
research (3005) 3005
international normalized ratio (2939) 2939
adolescent (2931) 2931
risk assessment (2819) 2819
aspirin - therapeutic use (2818) 2818
aspirin (2800) 2800
pregnancy (2757) 2757
dabigatran (2708) 2708
cardiology (2627) 2627
warfarin - adverse effects (2620) 2620
deep-vein thrombosis (2559) 2559
venous thrombosis - drug therapy (2453) 2453
rivaroxaban (2440) 2440
recurrence (2437) 2437
stroke - etiology (2401) 2401
hemorrhage (2352) 2352
atrial-fibrillation (2347) 2347
blood coagulation - drug effects (2345) 2345
heparin - adverse effects (2319) 2319
warfarin - administration & dosage (2222) 2222
thrombosis - prevention & control (2187) 2187
cardiac arrhythmia (2172) 2172
thrombosis - drug therapy (2156) 2156
incidence (2132) 2132
diagnosis (2091) 2091
thrombin (2075) 2075
drug therapy, combination (2072) 2072
prognosis (2066) 2066
venous thrombosis (2063) 2063
complications (2047) 2047
pulmonary embolism (2040) 2040
clinical neurology (2020) 2020
dosage and administration (2001) 2001
risk-factors (1978) 1978
internal medicine (1959) 1959
medical research (1946) 1946
venous thromboembolism - prevention & control (1925) 1925
bleeding (1917) 1917
thrombosis - etiology (1893) 1893
randomized controlled trials as topic (1883) 1883
glycosaminoglycans (1877) 1877
dose-response relationship, drug (1876) 1876
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (41) 41
Gerstein Science - Stacks (35) 35
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Collection Dvlpm't (Acquisitions) - Pharmacy (1) 1
Credit Valley Hospital - Closed Orders (1) 1
Gerstein Science - May be requested in 6-10 wks (1) 1
Mt Sinai Hospital - Online (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Scarborough Hospital - Online (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (53940) 53940
German (2226) 2226
French (1934) 1934
Spanish (847) 847
Russian (737) 737
Italian (551) 551
Japanese (395) 395
Polish (201) 201
Chinese (195) 195
Dutch (195) 195
Portuguese (110) 110
Danish (100) 100
Swedish (95) 95
Hungarian (93) 93
Czech (90) 90
Norwegian (67) 67
Romanian (66) 66
Finnish (63) 63
Hebrew (59) 59
Turkish (48) 48
Bulgarian (41) 41
Ukrainian (33) 33
Croatian (32) 32
Serbian (30) 30
Korean (17) 17
Lithuanian (15) 15
Slovak (13) 13
Icelandic (5) 5
Bosnian (3) 3
Arabic (2) 2
Persian (2) 2
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Circulation, ISSN 0009-7322, 09/2013, Volume 128, Issue 11, pp. 1234 - 1243
BACKGROUND—Patients experiencing major bleeding while taking vitamin K antagonists require rapid vitamin K antagonist reversal. We performed a prospective... 
CARDIAC & CARDIOVASCULAR SYSTEMS | ORAL ANTICOAGULANT REVERSAL | CLINICAL-TRIAL | RECOMBINANT FACTOR-VIII | vitamin K antagonist | prothrombin complex concentrates | PREVIOUSLY UNTREATED PATIENTS | INTRACRANIAL HEMORRHAGE | THERAPY | WARFARIN | TRANSFUSION | HEMOPHILIA-A | anticoagulants | PERIPHERAL VASCULAR DISEASE | plasma | FRESH-FROZEN PLASMA | hemorrhage | Single-Blind Method | Plasma | Prospective Studies | Thromboembolism - chemically induced | Factor IX - therapeutic use | Humans | Middle Aged | Male | Factor IX - adverse effects | Hemorrhage - prevention & control | Vitamin K - antagonists & inhibitors | Thromboembolism - prevention & control | Aged, 80 and over | Adult | Factor X - therapeutic use | Female | Factor X - adverse effects | Factor VII - adverse effects | Factor VII - therapeutic use | Emergencies | Anticoagulants - therapeutic use | Treatment Outcome | Prothrombin - therapeutic use | Anticoagulants - adverse effects | Prothrombin - adverse effects | Hemostatics - adverse effects | International Normalized Ratio | Hemorrhage - drug therapy | Blood Coagulation Factors - adverse effects | Anticoagulants - pharmacology | Blood Coagulation Factors - therapeutic use | Aged | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Drug Combinations | Antidotes - therapeutic use | Antagonists (Biochemistry) | Usage | Care and treatment | Blood coagulation factors | Health aspects | Hemorrhage | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article
2017, Advances in experimental medicine and biology, ISBN 9783319221083, Volume 906.
This unique publication explores diverse themes relating to thrombosis and embolism, from basic research at cell and molecular level to the actual care,... 
Anticoagulants | Venous Thromboembolism | Pulmonary Embolism | therapeutic use
Web Resource
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article